1.Trends in Axillary Surgery for Treating Ductal Carcinoma In Situ: A Korean Population-based Study
Young Duck SHIN ; Gilwon KANG ; Hoyeon JANG ; Young Jin CHOI
Journal of Breast Cancer 2021;24(1):49-62
Purpose:
Ductal carcinoma In Situ (DCIS) is common in South Korea. We evaluated the patterns of axillary surgery among patients with DCIS to highlight the need for compliance with the updated national guidelines. We also evaluated whether sentinel lymph node biopsy (SLNB) was performed in accordance with the national guidelines.
Methods:
The Korean Health Insurance Review and Assessment Service-National Inpatient Sample database was searched for patients with DCIS (2009–2015) to identify axillary surgery patterns by breast surgery type, year of diagnosis, age at diagnosis, and the location and volume of surgeries for DCIS at the hospital. The rates of SLNB and axillary dissection were compared using descriptive statistics and univariate analyses. Analyses were also conducted using the chi-squared test and multiple logistic regression analysis.
Results:
We identified 16,315 Korean women who underwent surgery for DCIS, including 11,292 cases of SLNB (69.2%) and 131 cases of axillary lymph node dissection (0.8%).Breast-conserving surgery (BCS) was performed in 10,323 patients (63.3%) with an SLNB rate of 56.0%, while total mastectomy (TM) was performed in 5,992 patients (36.7%), with an SLNB rate of 92.0%. During 2009–2015, the SLNB rate during TM increased from 88.23% to 92.80%. SLNB was influenced by hospital region and surgical volume, and hospitals performing low volumes of surgeries were significantly more likely to perform SLNB regardless of the surgery type (odds ratio, 1.372; 95% confidence interval, 1.265–1.488).
Conclusion
Although the Korean guidelines recommend SLNB for all TM procedures and select BCS procedures for DCIS, relatively high rates of SLNB were performed for BCS, and there was inter-hospital variability in performing SLNB. Improved compliance with the guidelines by the surgeons is critical for Korean patients with DCIS.
2.Trends in Axillary Surgery for Treating Ductal Carcinoma In Situ: A Korean Population-based Study
Young Duck SHIN ; Gilwon KANG ; Hoyeon JANG ; Young Jin CHOI
Journal of Breast Cancer 2021;24(1):49-62
Purpose:
Ductal carcinoma In Situ (DCIS) is common in South Korea. We evaluated the patterns of axillary surgery among patients with DCIS to highlight the need for compliance with the updated national guidelines. We also evaluated whether sentinel lymph node biopsy (SLNB) was performed in accordance with the national guidelines.
Methods:
The Korean Health Insurance Review and Assessment Service-National Inpatient Sample database was searched for patients with DCIS (2009–2015) to identify axillary surgery patterns by breast surgery type, year of diagnosis, age at diagnosis, and the location and volume of surgeries for DCIS at the hospital. The rates of SLNB and axillary dissection were compared using descriptive statistics and univariate analyses. Analyses were also conducted using the chi-squared test and multiple logistic regression analysis.
Results:
We identified 16,315 Korean women who underwent surgery for DCIS, including 11,292 cases of SLNB (69.2%) and 131 cases of axillary lymph node dissection (0.8%).Breast-conserving surgery (BCS) was performed in 10,323 patients (63.3%) with an SLNB rate of 56.0%, while total mastectomy (TM) was performed in 5,992 patients (36.7%), with an SLNB rate of 92.0%. During 2009–2015, the SLNB rate during TM increased from 88.23% to 92.80%. SLNB was influenced by hospital region and surgical volume, and hospitals performing low volumes of surgeries were significantly more likely to perform SLNB regardless of the surgery type (odds ratio, 1.372; 95% confidence interval, 1.265–1.488).
Conclusion
Although the Korean guidelines recommend SLNB for all TM procedures and select BCS procedures for DCIS, relatively high rates of SLNB were performed for BCS, and there was inter-hospital variability in performing SLNB. Improved compliance with the guidelines by the surgeons is critical for Korean patients with DCIS.
3.Deflazacort Increases Osteoclast Formation in Mouse Bone Marrow Culture and the Ratio of RANKL/OPG mRNA Expression in Marrow Stromal Cells.
Hoyeon CHUNG ; Young Soon KANG ; Chang Sun HWANG ; In Kul MOON ; Chang Hoon YIM ; Kyu Hong CHOI ; Ki Ok HAN ; Hak Chul JANG ; Hyun Koo YOON ; In Kwon HAN
Journal of Korean Medical Science 2001;16(6):769-773
Information on precise effects of deflazacort on bone cell function, especially osteoclasts, is quite limited. Therefore, the present study was undertaken to test effects of deflazacort on osteoclast-like cell formation in mouse bone marrow cultures and on the regulation of osteoprotegerin (OPG) and its ligand (RANKL) mRNA expressions by RT-PCR in the ST2 marrow stromal cells. TRAP-positive mononuclear cells increased after the treatment of deflazacort at 10(-9) to 10(-7) M alone for 6 days in a dose-dependent manner. Number of TRAP-positive multi-nucleated cells (MNCs) increased significantly with combined treatment of deflazacort at 10(-7) M and 1,25-(OH)2D3 at 10(-9) M compared to that of cultures treated with 1,25-(OH)2D3 alone (p<0.05). Exposure to deflazacort at 10(-7) M in the presence of 1,25-(OH)2D3 at 10(-9) M in the last 3-day culture had greater stimulatory effect on osteoclast-like cell formation than that of the first 3-day culture did. Deflazacort at 10(-10) -10(-6) M downregulated OPG and upregulated RANKL in mRNA levels in a dose-dependent manner. These observations suggest that deflazacort stimulate osteoclast precursor in the absence of 1,25-(OH)2D3 and enhance differentiation of osteoclasts in the presence of 1,25-(OH)2D3. These effects are, in part, thought to be mediated by the regulation of the expression of OPG and RANKL mRNA in marrow stromal cells.
Animal
;
Bone Marrow Cells/*cytology
;
Calcitriol/pharmacology
;
Calcium Channel Agonists/pharmacology
;
Carrier Proteins/*genetics
;
Cell Differentiation/drug effects
;
Cells, Cultured
;
Dexamethasone/pharmacology
;
Gene Expression/drug effects
;
Glucocorticoids, Synthetic/pharmacology
;
Glycoproteins/*genetics
;
Immunosuppressive Agents/*pharmacology
;
Male
;
Membrane Glycoproteins/*genetics
;
Mice
;
Mice, Inbred ICR
;
Osteoclasts/*cytology
;
Pregnenediones/*pharmacology
;
RNA, Messenger/analysis
;
Receptors, Cytoplasmic and Nuclear/*genetics
;
Stromal Cells/cytology
4.A case of small cell carcinoma of the rectum manifesting as pathologic femur neck fracture.
Jee Joo HWANG ; Seong Gook JEON ; Il Soon HWANG ; Eun Joo KIM ; Chang Hoon YIM ; Hoyeon CHUNG ; Ki Ok HAN ; Hak Chul JANG ; Hyun Koo YOON ; In Kwon HAN ; Woo Nam MOON ; Sung Ran HONG
Korean Journal of Medicine 2002;62(5):584-588
Small cell carcinoma of the colon and rectum is a rare primary epithelial malignancy at this location. Histologically, this tumor represents a spectrum of neuroendocrine differentiation. The neuroendocrine cancers of the colon manifest a highly aggressive behavior, even more than their adenocarcinoma counterpart of the same stage. Small cell carcinoma in the colon has early metastasis and the prognosis is extremely poor. We report a case of small cell carcinoma of the rectum manifesting as femur neck fracture during sleep.
Adenocarcinoma
;
Carcinoma, Small Cell*
;
Colon
;
Femoral Neck Fractures*
;
Femur Neck*
;
Femur*
;
Neoplasm Metastasis
;
Prognosis
;
Rectum*
5.COVID-19 Vaccination Rates in Patients With Chronic Medical Conditions:A Nationwide Cross-Sectional Study
Eliel NHAM ; Young-Eun KIM ; Jaehun JUNG ; Dong Wook KIM ; Hoyeon JANG ; Hakjun HYUN ; Hye SEONG ; Jin Gu YOON ; Ji Yun NOH ; Joon Young SONG ; Woo Joo KIM ; Hee Jin CHEONG
Journal of Korean Medical Science 2022;37(45):e325-
As most individuals acquire immunity to severe acute respiratory syndrome coronavirus 2, South Korea declared a return to normalcy a few months ago. However, epidemic waves continue because of endlessly emerging variants and waning immunity. Health authorities are focusing on those at high risk of severe coronavirus disease 2019 to minimize damage to public health and the economy. In this regard, we investigated the vaccination rates in patients with various chronic medical conditions by examining the national health insurance claims data and the national immunization registry. We found that patients with chronic medical conditions, especially those of higher severity, such as malignancy, had vaccination rates approximately 10–20% lower than those of the general population. Public health authorities and healthcare providers should try to vaccinate these patients to avoid preventable morbidity and mortality.